Introduction {#sec1}
============

The NOD.SCID *Il2rγ*^*−/−*^ (NSG) mouse strain dramatically improved investigators' ability to study human hematopoietic stem cell (HSC) engraftment ([@bib25; @bib30]). The NSG strain combines a series of mutations that inhibit the host's immune system by different mechanisms ([@bib2; @bib7; @bib11; @bib20; @bib29]). The NSG and other host strains require myeloablative conditioning (i.e., radiation) to achieve high levels of human chimerism ([@bib18; @bib30]). In addition to the effects of irradiation on the hematopoietic system that can promote engraftment ([@bib5]), confounding side effects of irradiation, including necrosis and apoptosis of gastrointestinal, neural, and muscle tissues, can lead to wasting, infection, and even death ([@bib15; @bib23]). Two recent studies report limited success in engrafting human HSCs into nonmyeloablated NSG hosts, but the chimerism achieved in the peripheral blood was modest (an average of 3% ± 3% and 18.3% ± 13%) ([@bib4; @bib6]).

Viable mutant *Kit oncogene* (*Kit*) murine strains support the engraftment of mouse hematopoietic cells without host irradiation ([@bib34]). The *Kit* (i.e., c-Kit, stem cell factor \[SCF\] receptor) encodes a type I membrane protein in the type III tyrosine kinase growth factor receptor family ([@bib36]), which is expressed on hematopoietic, melanocyte, neural, and germ cells ([@bib19; @bib22; @bib27]). When its ligand, SCF, binds to c-Kit, it induces receptor homodimerization and signal transduction ([@bib14]). The c-Kit is required for normal hematopoiesis, and viable mutants most closely resemble aplastic anemia ([@bib10]). Mouse hosts with mutations in *Kit* thus provide a competitive advantage for WT donor cells and allow the engraftment of HSCs with reduced or no irradiation ([@bib9; @bib35]). Until recently, these strains have been short-lifespan heterozygotes (e.g., *Kit*^*+/Wv*^), causing a burden on producing experimental hosts ([@bib8; @bib35]). We demonstrate that nonirradiated NBSGW mice are similar in chimerism to that achieved in irradiated NSG (irNSG) mice and that NBSGW mice also support the serial transplantation of HSCs.

Results {#sec2}
=======

Nonirradiated Xenograft NBSGW Mice Show Increased Chimerism in the Peripheral Blood when Compared with Non-irNSG Mice and Are Similar to Irradiated NSG Mice {#sec2.1}
------------------------------------------------------------------------------------------------------------------------------------------------------------

We outcrossed mice homozygous for the *Kit*^*W41*^ allele with the NSG strain. The resultant F1 triple-heterozygotes (*Prkdc*, *Il2rg*, *Sirpa, Kit*^*W41*^) were intercrossed and genotyped by Sanger sequencing for homozygotes of all four alleles (NBSGW). Nonalbino NBSGW mice displayed a Holstein coat with a prominent white stripe down the center of their head ([Figure 1](#fig1){ref-type="fig"}A). However, the NSG strain's albino coat color was inherited in 25% of the F2 progeny, making *Kit* status difficult to visually determine. To generate a strain devoid of albino animals and to allow for visual phenotyping for *Kit* status during the establishment of the strain, we selected for mice genotyping homozygous WT at the Tyrosinase allele ([@bib28]). Albino animals were absent from future generations.

To determine whether the homozygous *Kit*^*W41*^ allele would enhance human hematopoietic chimerism, we intravenously injected 2.5 × 10^5^ human CD34+ cord blood cells (CBCs) into the retro-orbital sinus of non-irNSG and NBSGW 8- to 10-week-old mice ([Figure 1](#fig1){ref-type="fig"}B). Every other week, peripheral blood was drawn and analyzed via flow cytometry for the presence of human and mouse blood cell surface proteins ([Figure 1](#fig1){ref-type="fig"}C). In two independent experiments (experiment 1, n = 3, [Figure 1](#fig1){ref-type="fig"}D; experiment 2, n = 5; [Figure 1](#fig1){ref-type="fig"}E) and at each independent time point, the NBSGW strain engrafted at higher levels than the NSG strain. At the 12-week time point, the average percentage of human chimerism observed in the NBSGW strain (61% ± 2%) measured 9-fold higher when compared with the parental control NSG strain (8.3% ± 1.2%; [Figures 1](#fig1){ref-type="fig"}D and 1E).

Both T cells (CD3+) and myeloid (CD11b+, CD15+, CD66b+) cells represented a similar percentage of human cells in both NSG and NBSGW hosts ([Table 1](#tbl1){ref-type="table"}). However, the percentage of B cells was significantly increased in the NBSGW strain (68.4% ± 2.9%) compared with the NSG strain (46.4% ± 3.2%, p \< 0.01).

We performed a separate experiment to investigate how comparable NBSGW mice are to the field's standard model: irNSG mice ([Figure 1](#fig1){ref-type="fig"}F). As described above, we injected 2.5 × 10^5^ human CD34+ CBCs into the retro-orbital sinus of the hosts and assessed the peripheral blood monthly for presence of human cells by flow cytometry. At the 12-week time point, both strains xenografted similarly indicating that genetic myeloablation may be similar to irradiating hosts (n = 3; [Figure 1](#fig1){ref-type="fig"}G).

NBSGW Mouse Marrow Contains Lymphoid, Myeloid, and Erythroid Human Cells {#sec2.2}
------------------------------------------------------------------------

At 12-weeks postengraftment, the NBSGW strain had a higher percentage of human cells in the bone marrow (97% ± 0.4%) compared with the NSG strain (30% ± 9%; p \< 0.01; [Figures 2](#fig2){ref-type="fig"}A and 2B). In addition, this corresponded to a higher percentage of human CD34+ in NBSGW marrow (18.6% ± 2.5%) compared with NSG marrow (6.4% ± 1.7%; [Figures 2](#fig2){ref-type="fig"}C and 2D available online). Glycophorin A (GlyA) analysis revealed a substantial presence of human erythroid cells in NBSGW marrow (26.4% ± 10.4%; [Figures 2](#fig2){ref-type="fig"}F and 2G), but not in NSG marrow (0.12% ± 0.04%). Further analysis of the hosts' peripheral blood did not reveal GlyA+ cells in circulation (data not shown). Furthermore, myeloid cells were present at a higher level in NBSGW marrow ([Figure 2](#fig2){ref-type="fig"}E), whereas human T cells (CD3+) and B cells (CD19+) in the bone marrow were at similar levels in both strains ([Table 1](#tbl1){ref-type="table"}).

Serial Transplantation and Normal HSC Development Occurs in the NBSGW Strain {#sec2.3}
----------------------------------------------------------------------------

To demonstrate effective development of long-term reconstituting HSCs in NBSGW marrow, we performed serial transplantation of HSCs. The primary NBSGW recipient received an injection of 2.5 × 10^5^ human CD34+ CBCs into the retro-orbital sinus ([Figure 2](#fig2){ref-type="fig"}H). At 16-weeks postxenotransplant, we assessed the primary recipient marrow for long-term reconstituting human cells by flow cytometry. We identified a population of human Lin^*−*^CD34^+^CD38^*−*^CD90^+^CD45RA^*−*^ cells in murine marrow, indicating that normal hematopoietic development was occurring in the NBSGW host ([Figure 2](#fig2){ref-type="fig"}I). We performed transplants of humanized marrow to secondary recipients (n = 4) and assessed the recipients' peripheral blood for de novo produced human cells. At both 6 and 12 weeks postengraftment, we observed human cells in the peripheral blood. At 12 weeks, 2.1% ± 1.0% of the leukocytes stained positive for human CD45 ([Figure 2](#fig2){ref-type="fig"}J). This trend increased from 6 to 12 weeks, indicating an expansion of the secondary graft. In addition, we observed multilineage reconstitution of the recipient with both lymphoid and myeloid components indicating successful secondary transplantation ([Table 1](#tbl1){ref-type="table"}).

Lymphoid Organs of Humanized NBSGW Mice Reconstitute with Human Cells and Begin to Recapitulate Immunocompetent Architecture {#sec2.4}
----------------------------------------------------------------------------------------------------------------------------

The spleen-to-body weight ratios from nonengrafted control NBSGW and NSG mice were, on average, six times smaller compared with those from immunocompetent C57BL/6J mice ([Figure 3](#fig3){ref-type="fig"}D) and lacked white lymphocyte pulp ([Figure 3](#fig3){ref-type="fig"}F). Xenografted NBSGW spleens almost tripled in size compared with their unengrafted NBSGW counterparts ([Figure 3](#fig3){ref-type="fig"}D) and had a restored white pulp ([Figure 3](#fig3){ref-type="fig"}F). Interestingly, on average, nonengrafted NBSGW spleens are smaller than spleens of the NSG strain ([Figure 3](#fig3){ref-type="fig"}F).

At 12-weeks postinjection, 94% ± 2% of the splenocytes in NBSGW were huCD45+ compared with 55% ± 13% in NSG spleens ([Figure 3](#fig3){ref-type="fig"}A). In agreement with the flow cytometry data, αhuCD45 staining of NBSGW spleen histological sections revealed more extensive staining than those of NSG spleens ([Figure 3](#fig3){ref-type="fig"}E). We also observed increased staining of NBSGW spleen sections for both myeloid (CD11b) and dendritic cells (CD1a) compared with NSG spleens ([Figure 3](#fig3){ref-type="fig"}E). Although the level of chimerism overall was higher in the NBSGW spleen, the percentage of the human cells that were T cells, natural killer T cells, and B cells was roughly similar in both strains ([Table 1](#tbl1){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}B). Analysis of the transitional CD19+ population signified a normal B cell maturation repertoire occurring in both strains of mice. Of the huCD45+CD19+ cells, 53% ± 3% stained positively for IgM in the NSG strain compared with 61% ± 4% in the NBSGW strain ([Figure 3](#fig3){ref-type="fig"}C; p = 0.013).

Thymuses were obtained from nonirradiated NBSGW mice (seven of eight), but we were unsuccessful in definitively identifying like thymic tissue in non-irNSG mice (zero of eight). This made a technical comparison challenging. However, we evaluated the NBSGW for both human MHCII and human CD3. The analysis indicated that thymuses were low in staining for human MHCII, yet CD3 staining was found to be in abundance within the tissue ([Figure 3](#fig3){ref-type="fig"}G). Further, analysis indicated a lack of thymic structure with a very disorganized cortex and nonexistent medulla.

Discussion {#sec3}
==========

In this study, we generated mice homozygous for *Prkdc*^*scid*^, *Il2rγ*^*−*/*−*^, *Kit*^*W41*^, and NOD *Sirpa* alleles and showed that the resultant NBSGW model supports robust levels of humanization in peripheral blood, bone marrow, and spleen in the absence of irradiation. The observed levels of de novo derived human HSCs in NBSGW mice are significantly higher than the values previously reported for unconditioned NSG or NSG-transgenic mice ([@bib4; @bib6]). In our studies, the unconditioned NBSGW strain supported levels of human chimerism in peripheral blood that was 9-fold higher (average 61% versus 8.3%) compared with the unconditioned NSG strain. Furthermore, these levels are equivalent to those recently reported in multiple irradiated *Rag2*^*−/−*^ *Il2γ*^*−/−*^ mice possessing humanized loci for *TPO*, *CSF1*, *IL3*, and *CSF2* in which hematopoietic development is enhanced ([@bib24; @bib26]). We further demonstrate, through serial transplantation, robust normal development of human HSCs in NBSGW marrow and the developing HSCs ability to repopulate a secondary recipient. To our knowledge, *Kit*^*W41/41*^ mutants when combined with NSG mice yield the highest level of human hematopoietic chimerism obtained in any mouse strain without conditioning by ionizing radiation.

While this manuscript was in review, four *Kit* mutant strains on either the BALB/c *RAG1*^*−/−*^ (BRg *Kit*^*Wv/Wv*^, BRgWv) or NSG (NSG *Kit*^*Wv/Wv*^, NSGWv; NSGWv/+, and NSGW41) backgrounds were described ([@bib8]). These strains are similar to the NBSGW model exhibiting comparable humanization potential in the absence of irradiation. Both BALB/c and NOD immunodeficient-based strains support varied types of humanization. However, NOD background strains have higher humanization potential ([@bib3]) primarily resulting from polymorphisms in the *Sirpa* gene that prevents the NOD macrophages from engulfing human cells ([@bib33]). Hence, the *Kit* mutant strains NBSGW, NSGWv, NSGWv/+, and NSGW41 are better suited recipients when compared with the BRgWv strain. Homozygous *Kit*^*Wv*^ NSG mice have a low life expectancy, making the NSGWv/+ the more useful of the two for long-term experiments ([@bib8]). However, genotyping to identify suitable NSGWv/+ recipients among litters is time consuming.

Our goal was to generate a viable homozygous strain that would engraft with high efficiency without irradiation. Based on previously reported *Kit* mutant phenotypes ([@bib10]), we hypothesized that the *Kit*^*W41*^ could be maintained as a homozygous line when crossed with the NSG, and the contribution of the NSG strain would boost the efficiency of humanization in the absence of irradiation. While the NBSGW is a mixed NOD and C57BL/6J background, the Cosgun strain is a congenic NOD also incorporating a homozygous *Kit*^*W41*^ allele. A direct comparison of engraftment results between the two strains is currently difficult due to differences in experimental approaches (e.g., cell numbers and sources) and reported postengraftment end points (e.g., 12 weeks versus up to 40 weeks). However, the highest levels of engraftment in the absence of irradiation were observed in homozygous *Kit*^*W41*^ immunocompromised mice in both studies, potentially indicating that a mixed background is inconsequential given the correct genetic elements. Based on these arguments, either the NBSGW or the NSGW41 strains are of choice over their contemporary strains in the absence of irradiation and may prove as a widely enabling resource.

In addition to the increased human chimerism in the blood, we observed a significantly greater percentage of de novo human erythroid cells in the marrow of NBSGW mice (average 26.0% versus 0.1%). These levels are ∼5--12 times higher on average than previous reports with irNSG mice ([@bib12; @bib18]). However, our analysis of peripheral blood for GlyA+ cells did not indicate we had achieved circulating human erythrocytes, suggesting that the current mouse model still lacks signals to complete human erythrogenesis.

The NBSGW mice exhibit a high degree of human chimerism, albeit a bias in differentiation of the engrafted human hematopoietic cells remains. In normal human peripheral blood, granulocytes, T cells, and B cells are present at 53%, 20%, and 33%, respectively ([@bib25]), but within our study, they are present at 2.5%, 3.3%, and 68%, respectively. These biases are comparable to those previously observed in other mouse xenograft models ([@bib3; @bib8; @bib18]) and suggest that deficiencies exist in species cross-reactivity of signaling molecules supporting typical human hematopoietic cell distributions ([@bib25]). Additional genetic modifications to NBSGW mice are possible with the aim of eliminating these biases. Such modifications might include replacing growth factors or matrix molecules that poorly cross-react between mouse and human species. A number of recently described strains, when crossed with NBSGW, might further improve the differentiation of human HSCs ([@bib1; @bib4; @bib26]).

Although the main focus of our study was to grade the relative efficiency of human HSC engraftment in a nonirradiated mouse model, the lack of T cell production in NBSGW, NSGW41 and NSG warrants further discussion. All three strains support the production of a limited number of T cells ([@bib8]). This may be partially due to a relatively thin thymic membrane and to the documented poor thymic microenvironment ([@bib18; @bib30]) for all strains. Furthermore, in this study, we measured engraftment at 12 weeks, while T cell development is building and not yet plateaued ([@bib13]). However, the data and reports indicate that T cell production is elevated in the homozygous *Kit*^*W41*^ strains in comparison to others ([@bib8]). In sum, these facts create an opportunity to improve humanized murine models via the improvement of thymic function. Pluripotent stem cell (PSC) technology offers one potential route to re-establish human thymic function in humanized mouse models ([@bib32; @bib37]). For example, two recent publications report the correction of a developmental T cell deficiency in immunocompromised mice ([@bib21; @bib31]). After differentiating human embryonic stem cells to a thymic epithelial progenitor cell type and grafting these cells into mice, the authors produced human thymic structures capable of further development and education of both mouse and human T cells in vivo ([@bib21; @bib31]). Thus, further refinements of PSC technology may afford even better opportunities to study allogeneic and autologous human HSC transplantation in the in vivo mouse environment.

A variety of suitable murine xenograft models are currently used in hematopoietic research, yet these animals require conditioning prior to experimentation. Given the increasingly restricted access to radiation sources, NBSGW mice are broadly enabling, allowing laboratories without access to radiation to accelerate human hematopoietic research. The NBSGW model and other homozygous mice possessing the *Kit*^*W41*^ allele are significant steps toward providing a standardized framework and an improved understanding of human HSC biology.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

The C57BL/6.*Kit*^*W41*^ and the NSG strains were obtained from the Jackson Laboratory ([@bib10; @bib30]). The NSG mouse strain was intercrossed with mice homozygous for the *Kit*^*W41*^ allele and the resultant progeny bred (NBSGW) to homozygosity (for *Prkdc*^*scid*^, *Il2rg*^*−*^, *Kit*^*W41*^, *Sirpa*^*NOD*^, *Tyr*^*A*^). The NBSGW mice (JAX Stock No. 026622) were maintained as homozygotes. All breeding males were retired after 1 year of age. See [Supplemental Experimental Procedures](#app2){ref-type="sec"} for oligos and allelic determination. The University of Wisconsin Medical School's Animal Care and Use Committee authorized all experiments.

Human Cell Engraftment {#sec4.2}
----------------------

Frozen human CD34+ CBCs (AllCells) were thawed per manufacturer's recommendation and incubated overnight in serum-free media (STEMCCELL Technologies) supplemented with human SCF (100 ng/ml; Peprotech). The next morning, live cells were counted using a hemocytometer and trypan blue. Cells were suspended at 1.25 × 10^6^ per ml in a 10 mM HEPES buffered Hank's balanced salt solution (Life Technologies). Eight- to 10-week-old male mice anesthetized with isoflurane were injected retro-orbitally with 200 μl cell suspension. Serial transplants were conducted using bone marrow cells recovered from mice engrafted with CD34+ CBCs. Irradiation of NSG mice was carried out using an X-RAD 320ix irradiator (Precision X-Ray) at 250 RAD.

Human Xenograft Analysis {#sec4.3}
------------------------

A 50 μl blood sample was drawn into heparin-coated capillary tubes from the retro-orbital sinus and processed for flow cytomteric analysis. At 12-weeks postengraftment, tissues were removed for analysis. Multipotent progenitor analysis was performed as previously described ([@bib16]). See the [Supplemental Experimental Procedures](#app2){ref-type="sec"} for processing and antibodies. Flow cytometry was performed on a BD AriaIII and analyzed using FlowJo Version 9.5.2 (Tree Star).

Statistics {#sec4.4}
----------

A two-sided Wilcoxon rank-sum test was performed using the statistical software program MStat 5.5 (<http://mcardle.oncology.wisc.edu/mstat/>) to determine the statistical significance between experimental groups; n = number of experimental mice per group.

Histology and Immunohistochemistry {#sec4.5}
----------------------------------

Tissues were fixed in 10% neutral-buffered formalin, processed at the University of Wisconsin Veterinary School Histology Lab, and developed as previously described ([@bib17]). Slides were analyzed on a Zeiss AxioScope-A1 with EC Plan-NeoFluar −5× or −40×/0.75 objectives, and images acquired using a Q-Imaging Micropublisher 3.3RTV camera and iVision v.4.5.0.
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![Nonirradiated NOD,B6.*Prkdc*^*scid*^*Il2rg*^*tm1Wjl/SzJ*^*Kit*^*W41/W41*^ (NBSGW) Mice Are Similar to Their irNSG Counterparts and Exhibit High Levels of Human Chimerism in the Absence of Irradiation\
(A) An NBSGW mouse.\
(B) Experimental design of nonirradiation comparisons.\
(C) Representative flow cytometry plots of non-irNSG and NBSGW mice 12-weeks postengraftment and analysis of mouse and human CD45.\
(D and E) Biweekly monitoring of the human chimerism in the peripheral blood of non-irNSG and of NBSGW mice. Error is represented by SD (n = 3 and n = 5, ^∗^p \< 0.01, ^∗∗^p \< 0.05).\
(F) Experimental design of irNSG versus nonirradiated NBSGW.\
(G) Monthly monitoring comparison of the human chimerism in peripheral blood of irNSG and of nonirradiated NBSGW strains. Error is represented by SD, n = 3, comparison only, not significant.](gr1){#fig1}

![Xenotransplanted Nonirradiated NBSGW Mice Exhibit Increased Humanization in the Marrow and Are Conducive to Serial Transplantation\
(A) The percentage of observed human CD45+ leukocytes in the bone marrow of non-irNSG (white) and NBSGW (gray) mice at 12-weeks postengraftment.\
(B) Representative mouse CD45 versus human CD45 12-week flow cytometry plot comparison between non-irNSG and NBSGW mice.\
(C) The observed percentages of human CD34+ cells in the human CD45+ fraction of the mouse marrow (NSG, white; NBSGW, gray).\
(D) Representative flow cytometry analysis plot comparison between non-irNSG and NBSGW mice.\
(E) The observed percentages of human CD33+ cells observed in the human CD45+ fraction of the mouse marrow (NSG, white; NBSGW, gray).\
(F) The observed percentage of human GlyA+ cells observed in the mouse marrow (NSG, white; NBSGW, gray).\
(G) Representative flow cytometry analysis plot comparison between non-irNSG and NBSGW mice.\
(H) Experimental design of nonirradiation NBSGW serial transplantation.\
(I) Representative flow cytometry analysis of CD34 enriched Lin−CD34+CD38−CD90+CD45RA− cells isolated from the NBSGW marrow at 16 weeks.\
(J) Observed human chimerism at both 6 and 12 weeks in secondary NBSGW recipients. (Error is represented by SD, ^∗^p \< 0.01).](gr2){#fig2}

![Human Chimerism, Lineage Development and Gross Pathology Observed in Lymphoid Organs of Non-irNSG (White) and NBSGW (Gray) Mice at 12-Weeks Postengraftment\
(A) The percentage of human CD45+ splenocytes (non-irNSG \[white\] and NBSGW \[gray\]).\
(B and C) The percentage of human (B) CD19+ cells and (C) CD19+IgM+ cells observed in the human CD45+ fraction.\
(D) The ratio of spleen:mouse weight in basal state (unengrafted, n = 4) and two xenograft experiments (C57BL/6J; dark gray, experiment 1, n = 5; experiment 2, n = 3). Error is represented by SD (^∗^p \< 0.01).\
(E) Representative photomicrographs of sectioned spleens of non-irNSG and NBSGW mice at 12-weeks postengraftment (based on flow cytometry data). Spleens were stained with anti-human CD45 (splenocyte), anti-human CD19 (B cell), anti-human CD11b (myeloid), and anti-human CD1a (dendritic) and were counterstained with hematoxylin (blue; the black scale bar is 20 μm).\
(F) Photomicrographs of hematoxylin (blue) and eosin (red) stained spleens from nonirradiated, nonengrafted mouse strains (left), and nonirradiated humanized mice at 12 weeks (right; white scale bar represents 400 μm).\
(G) Representative photomicrographs of sectioned thymus from non-irradiated NBSGW mice at 12-weeks postengraftment; anti-human MHCII (top), anti-human CD3 (middle), and hematoxylin (blue) and eosin (red) stained (bottom; white scale bar represents 400 μm; black scale bar represents 20 μm).](gr3){#fig3}

###### 

Observed Percentages of Human CD45+ Cells at 12-Weeks Postxenograft or Serial Transplant in Hematopoietic Compartments of Nonirradiated Mice

  Location                       Marker (Cell)              NSG (%)         NBSGW (%)
  ------------------------------ -------------------------- --------------- ------------
  Peripheral Blood               CD3+ (lymphoid, T cell)    3.1 ± 2.0       3.3 ± 1.5
  CD19+ (lymphoid, B cell)       46.4 ± 3.2                 68.4 ± 2.9^∗^   
  CD11b+ (myeloid)               3.4 ± 1.4                  2.5 ± 0.5       
  CD15+ (Neut, Eos, Mono)        2.4 ± 2.2                  1.4 ± 0.2       
  CD66b+ (Gran)                  2.5 ± 1.5                  2.1 ± 0.3       
  Bone Marrow                    CD3+ (lymphoid, T cell)    3.5 ± 0.5       5.4 ± 1.0
  CD19+ (lymphoid, B cell)       86.0 ± 2.0                 89.0 ± 1.1      
  CD19+IgM+ (lymphoid, B cell)   0.3 ± 0.1                  0.5 ± 0.1       
  Spleen                         CD3+ (lymphoid, T cell)    3.6 ± 1.5       3.0 ± 1.5
  CD56^low^/+ (NKT cell)         0.8 ± 0.3                  1.0 ± 0.3       
  Secondary Graft                CD3+ (lymphoid, T cell)    ND              0.3 ± 0.6
  Peripheral Blood               CD19+ (lymphoid, B cell)   ND              87.8 ± 4.6
  CD11b+ (myeloid)               ND                         8.5 ± 6.5       

Error is represented by SD (n = 5, ^∗^p \< 0.01). Eos, eosinophil; Gran, granulocyte; Mono, monocyte; ND, not determined; Neut, neutrophil.
